AbCellera Biologics coverage initiated with overweight rating and $17 target
ABCL•JPMorgan initiated coverage of AbCellera Biologics with an overweight rating and a $17 price target.
Related News
Largo prices offering with 10,200,000 share warrants exercisable at US$0.70
LGO•
PPL Corp: Scotiabank initiates coverage with sector outperform rating; price target $36
PPL•
Techwing extends Micron Malaysia supply deal end date to Nov. 6 from Oct. 2
MU•
US stock futures flat as tech bounce meets crude-driven caution
SPY•
Low Rhine levels hamper shipping, weighing on German industry
EWG•